Key Points
- EVP Paul Mahon sold 8,300 United Therapeutics shares at an average price of $564.95, generating approximately $4.69 million. His remaining stake totaled 45,172 shares, a 15.52% reduction in ownership.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of forecasts and declined 1.9% year over year.
- The stock has a “Moderate Buy” consensus rating with a $621 average price target. A recent court ruling that Liquidia’s Yutrepia infringes United Therapeutics patents could help protect the company’s Tyvaso franchise, though appeals and regulatory actions remain possible.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the firm's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $564.95, for a total transaction of $4,689,085.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $25,519,921.40. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
United Therapeutics Trading Up 5.4%
United Therapeutics stock opened at $571.38 on Friday. The company has a fifty day simple moving average of $510.03 and a 200-day simple moving average of $539.64. The stock has a market cap of $24.51 billion, a P/E ratio of 20.44, a price-to-earnings-growth ratio of 2.72 and a beta of 0.49. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the company posted $6.41 earnings per share. United Therapeutics's revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in UTHR. Callan Family Office LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $1,217,000. Nicholas Investment Partners LP grew its position in shares of United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock worth $2,218,000 after acquiring an additional 3,766 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $3,359,000. Havemeyer Place LP acquired a new position in shares of United Therapeutics in the 4th quarter valued at $2,189,000. Finally, Seven Fleet Capital Management LP purchased a new stake in United Therapeutics in the 4th quarter valued at $633,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on UTHR shares. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. Weiss Ratings downgraded shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a report on Thursday, September 24th. They issued a "sell" rating and a $321.00 target price for the company. Finally, Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $621.00.
Get Our Latest Stock Analysis on United Therapeutics
More United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: A Delaware federal court found that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patent claims were invalid, strengthening the outlook for United Therapeutics’ Tyvaso products. United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
- Positive Sentiment: The ruling may limit Yutrepia’s ability to compete in the PH-ILD market and could support a request for the FDA to withdraw or restrict approval of Yutrepia until labeling excluding the disputed indication is approved. Investors therefore see a potentially longer period of market protection and more durable cash flow for the Tyvaso franchise. UTHR Prevails in LQDA's Yutrepia Patent Dispute
- Neutral Sentiment: The legal victory is not necessarily the end of the dispute, and further proceedings, appeals, or regulatory actions could affect how quickly United Therapeutics benefits commercially. Analyst commentary has also turned more favorable, adding support to the move, although specific details on the latest recommendation were limited. United Therapeutics Analyst Turns Bullish
- Negative Sentiment: Several insiders sold shares, including CEO Martine Rothblatt, who sold a combined 9,500 shares, and EVP Paul Mahon, who sold 8,300 shares. These transactions reduced their holdings but may have been conducted under prearranged trading plans; they are a modest counterpoint to the positive litigation news rather than evidence of a change in business outlook. SEC insider transaction filing
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
